Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer

Ozgur E., Ferhatoglu F., Sen F., Saip P., Gezer U.

CANCER BIOMARKERS, vol.27, no.1, pp.11-17, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 1
  • Publication Date: 2020
  • Doi Number: 10.3233/cbm-190085
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.11-17
  • Keywords: Breast cancer, neoadjuvant chemotherapy, pathological complete response, long non-coding RNAs, blood plasma, NONCODING RNA H19, THERAPY, PLASMA, TUMOR
  • Istanbul University Affiliated: Yes


BACKGROUND: Novel biomarkers are needed to predict the effectiveness of the treatment of presurgical neoadjuvant chemotherapy (NAC) in breast cancer (BC).